GLP-1 TV · 9 videos · newest first
CagriSema explained videos
CagriSema is not FDA-approved, so these are trial readouts and explainers only, never personal-use videos. How it works and what the trials found. 9 videos, all playable here. For the label facts in writing, read our our guide.
17:36Mounjaro vs CagriSema: O Que os Estudos MostramGi BettinDetails
A video explains how Mounjaro works and what the evidence says.
Everything about this video
1:05:04Zepbound VS Cagrisema: Novo BESTED Lilly? Not so Fast…On The Pen™ GLP-1 NewsDetails
A news or media piece explains how Zepbound works and what the evidence says.
Everything about this video
49:34Reatrutide + Cagrilintide Scientific Study?!On The Pen™ GLP-1 NewsDetails
A news or media piece explains how a GLP-1 works and what the evidence says. Also covers the trials.
Everything about this video
7:53CagriSema Dr EXPLAINS How This GLP 1 + Amylin Drug Differs From WegovyDr. G's Lifestyle Medicine NetworkDetails8 key moments
According to the video, CagriSema is an investigational weekly injection that combines two drugs in one fixed dose: semaglutide, a GLP-1 receptor agonist, and cagrilintide, a long-acting amylin analog that also activates calcitonin receptors.
- 0:00 Introduction to Kagrama
- 0:21 Mechanism of action
- 1:34 Clinical trial data
- 3:14 Outperforming monotherapy
- 4:04 Patient impact and limits
- 4:42 Safety and health management
- 5:49 Future and implementation
- 6:55 Takeaways and contact
24:38**NEW** Cagrisema Data!On The Pen™ GLP-1 NewsDetails7 key moments
In this live stream from On The Pen, the speaker covers new CagriSema data for people with type 2 diabetes. He says Novo Nordisk released a 68-week readout in which patients on the high dose lost 15% of their body weight.
- 0:00 Video introduction
- 3:02 Medicare coverage update
- 8:01 Kaggrama data release
- 10:39 Market and youth usage
- 13:24 Personal experience and risks
- 17:31 Hunger management and products
- 22:53 Future pipeline and wrap up
- Side effects mentioned: fatigue
4:35Doctor Reviews Cagrisema: New Boosted Ozempic!Dr KiddDetails3 key moments
In this video, the channel, a general practitioner from Australia, explains CagriSema, a combination drug from Novo Nordisk's field of GLP-1 treatments.
- Side effects mentioned: nausea and vomiting
4:05Cagrilintide - New Rx? (Obesity Doctor)Weight Medicine with Dr. Meghan MDDetails4 key moments
In this 4-minute video, the speaker introduces cagrilintide, which she describes as a weight medication that is on the horizon and likely to be approved in the near to semi near future. She says it is made by Novo Nordisk and is not a GLP-1 medication.
- 0:00 Introduction to krillintide
- 0:39 What is krillintide?
- 1:23 How krillintide works
- 2:28 Future combined treatments
13:02CAGRISEMA: Breaking Down NEW Weight-Loss Solution | Obesity Medicine | Dr. Dan Obesity ExpertDr. Dan | Obesity ExpertDetails
A video explains how a GLP-1 works and what the evidence says.
Everything about this video
2:18#zepbound vs #cagrisema ( #Wegovy / cagrilintide combo) Head to Head in new phase 3 trial!On The Pen™ GLP-1 NewsDetails
According to the video, Novo Nordisk is starting a clinical trial that compares its own combination drug against Zepbound (tirzepatide). The narrator says the combination pairs semaglutide, a GLP-1 agonist, with cagrilintide, which is described as an amylin agonist.
Everything about this videoWatched enough? See what it costs.
Every GLP-1 program we track, ranked by what actually leaves your account.



